BTIG Research Raises Oruka Therapeutics (NASDAQ:ORKA) Price Target to $73.00

Oruka Therapeutics (NASDAQ:ORKA) had its target price lifted by investment analysts at BTIG Research from $63.00 to $73.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective would indicate a potential upside of 132.93% from the company’s previous close.

A number of other equities research analysts have also issued reports on the stock. Barclays initiated coverage on shares of Oruka Therapeutics in a research note on Monday, October 13th. They issued an “overweight” rating and a $48.00 target price on the stock. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Jefferies Financial Group started coverage on Oruka Therapeutics in a report on Thursday, November 13th. They set a “buy” rating and a $45.00 target price on the stock. Piper Sandler initiated coverage on shares of Oruka Therapeutics in a research note on Thursday, December 18th. They set an “overweight” rating and a $75.00 target price for the company. Finally, Guggenheim initiated coverage on shares of Oruka Therapeutics in a research report on Monday, October 27th. They issued a “buy” rating and a $60.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $50.67.

Oruka Therapeutics Trading Up 2.1%

Oruka Therapeutics stock opened at $31.34 on Monday. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $32.64. The stock has a market cap of $1.52 billion, a P/E ratio of -16.49 and a beta of -0.39. The stock has a 50 day moving average of $29.31 and a 200-day moving average of $21.74.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. As a group, equities analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $30.61, for a total transaction of $214,270.00. Following the completion of the transaction, the insider owned 1,518 shares of the company’s stock, valued at approximately $46,465.98. The trade was a 82.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 24.69% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Hedge funds have recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in Oruka Therapeutics during the 2nd quarter valued at about $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Oruka Therapeutics during the second quarter worth approximately $31,000. BNP Paribas Financial Markets boosted its position in shares of Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares during the period. PNC Financial Services Group Inc. bought a new position in Oruka Therapeutics in the 3rd quarter worth approximately $39,000. Finally, Russell Investments Group Ltd. acquired a new stake in Oruka Therapeutics in the 3rd quarter valued at approximately $43,000. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.